These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 39016729)

  • 1. A New Era for Obesity Drugs: Costly medications work well, but are they safe over the long term?
    Wallis C
    Sci Am; 2022 May; 326(5):26. PubMed ID: 39016729
    [No Abstract]   [Full Text] [Related]  

  • 2. The Benefit of Healthy Lifestyle in the Era of New Medications to Treat Obesity.
    Dalle Grave R
    Diabetes Metab Syndr Obes; 2024; 17():227-230. PubMed ID: 38249154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond Weight Loss: Added Benefits Could Guide the Choice of Anti-Obesity Medications.
    Guglielmi V; Bettini S; Sbraccia P; Busetto L; Pellegrini M; Yumuk V; Colao AM; El Ghoch M; Muscogiuri G
    Curr Obes Rep; 2023 Jun; 12(2):127-146. PubMed ID: 37209215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What are the risks and the benefits of current and emerging weight-loss medications?
    Robinson JR; Niswender KD
    Curr Diab Rep; 2009 Oct; 9(5):368-75. PubMed ID: 19793507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
    Tak YJ; Lee SY
    Curr Obes Rep; 2021 Mar; 10(1):14-30. PubMed ID: 33410104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obesity pharmacotherapy - update 2023.
    Haluzík M; Müllerová D; Sucharda P; Boženský J; Holéczy P; Fried M; Hainer V; Kunešová M; Málková I; Slabá Š; Šrámková P; Braunerová RT
    Cas Lek Cesk; 2023; 162(1):19-31. PubMed ID: 37185039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drugs to treat obesity: do they work?
    Kim S
    Postgrad Med J; 2016 Jul; 92(1089):401-6. PubMed ID: 27053517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of medications approved for chronic weight management.
    Fujioka K
    Obesity (Silver Spring); 2015 Apr; 23 Suppl 1():S7-11. PubMed ID: 25900872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new era in gut hormone-based pharmacotherapy for people with obesity.
    Firman C; Batterham RL
    Proc Nutr Soc; 2022 Sep; 81(3):217-226. PubMed ID: 36069071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New drug therapies for the treatment of overweight and obese patients.
    Mahgerefteh B; Vigue M; Freestone Z; Silver S; Nguyen Q
    Am Health Drug Benefits; 2013 Sep; 6(7):423-30. PubMed ID: 24991373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-obesity weight loss medications: Short-term and long-term use.
    Jeong D; Priefer R
    Life Sci; 2022 Oct; 306():120825. PubMed ID: 35870619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon receptor poly-agonists: a new era in obesity pharmacotherapy.
    Malik IO; Petersen MC; Klein S
    Obesity (Silver Spring); 2022 Sep; 30(9):1718-1721. PubMed ID: 35872608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term drug treatment for obesity: a systematic and clinical review.
    Yanovski SZ; Yanovski JA
    JAMA; 2014 Jan; 311(1):74-86. PubMed ID: 24231879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should the Same Safety Scrutiny of Antiobesity Medications be Applied to Other Chronic Usage Drugs?
    Halpern B; Mancini MC
    Obesity (Silver Spring); 2020 Jul; 28(7):1171-1172. PubMed ID: 32374528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-obesity Medications: Ethical, Policy, and Public Health Concerns.
    Klitzman R; Greenberg H
    Hastings Cent Rep; 2024 May; 54(3):6-10. PubMed ID: 38842904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obesity medications: what does the future look like?
    Butsch WS
    Curr Opin Endocrinol Diabetes Obes; 2015 Oct; 22(5):360-6. PubMed ID: 26313898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between industry payments and prescribing costly medications: an observational study using open payments and medicare part D data.
    Sharma M; Vadhariya A; Johnson ML; Marcum ZA; Holmes HM
    BMC Health Serv Res; 2018 Apr; 18(1):236. PubMed ID: 29609611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalizing Diabetes Management in Liver Transplant Recipients: The New Era for Optimizing Risk Management.
    Richardson B; Khan MQ; Brown SA; Watt KD; Izzy M
    Hepatol Commun; 2022 Jun; 6(6):1250-1261. PubMed ID: 34921530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Employer benefit design considerations for the era of biotech drugs.
    Vogenberg FR; Holland JP; Liebeskind D
    J Occup Environ Med; 2007 Jun; 49(6):626-32. PubMed ID: 17563605
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.